Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

Biologics may cause side effects. The most common side effects are redness, itching, bruising, and pain at the injection site. You’ll need to take a TB test before you start biologic therapy.

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

If you have psoriasis, you may feel like this autoimmune disease is plenty to cope with all on its own. But unfortunately there are a number of other health issues linked to the condition.

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

We review novel biologic agents targeting the T-helper 17 axis, including therapies directed towards interleukin (IL)-17 (secukinumab, ixekizumab, bimekizumab), IL-17R (brodalumab), IL-12/23p40 ...

In recent years, treatment for psoriasis and psoriatic arthritis has improved drastically with the widespread usage of biologics. Biologics, also known as biologic response modifiers, are ...